Lakefront Biotherapeutics NV

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss $45.5m $55.9m
Profit or Loss $54.0m ($115.7m) ($29.3m) $149.8m ($305.4m) ($103.2m) ($218.0m) $211.7m $74.1m $320.9m
Other Adjustments To Reconcile Profit Loss $4.1m
Adjustments For Share-Based Payments $11.0m $16.5m $26.8m $38.3m $80.0m $70.7m $88.5m $56.7m $19.9m $24.0m
Change in working capital other than deferred income ($10.9m) ($12.9m) $19.9m $12.7m ($146.1m) $23.3m ($32.3m) ($31.4m) ($61.4m) $149.3m ($964.3m)
Cash used for other liabilities related to the acquisition of subsidiaries ($28.2m) ($3.6m) ($1.8m)
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities $7k $0 $0 $49k $739k $2.4m $3k $462k
Purchase of property, plant and equipment ($4.5m) ($5.3m) ($10.4m) ($22.4m) ($42.5m) ($54.2m) ($27.4m) ($18.7m) ($16.7m) ($13.7m)
Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates $52.5m $1.1m
Purchase of financial investments $0 ($4.8b) ($4.6b) ($2.7b) ($3.4b) ($3.3b) ($3.5b)
Investment income received related to current financial investments $0 $5.1m $3.5m $12k $3.0m $14.8m $29.5m $60.4m
Sale of current financial investments $0 $1.1b $5.4b $2.1b $1.6b $3.5b $3.7b $3.7b
Net cash flows generated from/used in (-) investing activities ($7.3m) ($549k) ($15.9m) ($3.8b) $757.3m $541.2m ($1.2b) $71.2m $220.6m $288.8m
Payment of lease liabilities and other debts ($65k) ($5k) ($5.1m) ($6.2m) ($7.2m) ($8.2m) ($6.8m) ($4.9m) ($3.3m)
Net cash flows used in financing activities $396.0m
$353.4m -10.77%
$287.9m -18.53%
$1.3b +364.00%
$22.0m -98.35%
($3.9m) -117.59%
($1.5m) +61.64%
($5.0m) -236.31%
($4.9m) +1.54%
($3.3m) +33.53%
Increase/decrease (-) in cash and cash equivalents $205.8m $129.5m $779.7m $352.0m $33.5m ($1.7b) ($339.8m) ($104.4m) $28.1m
Cash and cash equivalents at beginning of year $340.3m $973.2m $1.2b $1.3b $1.9b $2.2b $508.1m $166.8m $64.2m $87.9m $108.1m
Effect of exchange rate differences on cash and cash equivalents $4.8m ($27.8m) $10.1m ($10.0m) ($70.5m) $56.8m $22.3m ($1.5m) $1.8m ($4.5m)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Additional Financial Items
Adjustments For Decrease Increase In Trade Account Receivable ($13.0m) ($27.7m) $76k $67.3m ($177.2m) ($79.9m) $69.0m ($39.1m) ($31.1m) $86.6m
Adjustments For Income Tax Expense $2.1m $2.4m $2.8m $11.7m ($1.7m) ($18.1m)
Adjustments For Increase Decrease In Trade Account Payable $2.1m $14.8m ($20.0m) ($79.9m) $31.2m $35.4m ($2.1m) $31.8m ($53.4m) $33.8m
Adjustments For Unrealised Foreign Exchange Losses Gains ($10.1m)
General And Administrative Expense $21.7m $24.4m $35.6m $73.7m $118.8m $140.9m $144.9m $128.3m $117.2m $147.3m
Goodwill $69.8m $69.6m $70.0m $0
Income Taxes Paid Refund Classified As Operating Activities $1.8m $199k $8k $57k $1.4m $684k $4.4m $8.2m ($406k) $372k
Interest Paid Classified As Operating Activities $47k $273k $1.1m $1.2m $9.0m $12.5m $12.5m $3.8m $689k $464k
Interest Received Classified As Operating Activities $1.1m $1.3m $4.6m $7.9m $10.1m $2.9m $4.8m $69.9m $97.5m $51.3m
Payments Of Lease Liabilities Classified As Financing Activities $5.1m $6.2m $7.2m $8.2m $6.8m $4.9m $3.3m
Proceeds From Disposal Or Maturity Of Availableforsale Financial Assets $372k $2.4m $82k $6.6m $4.0m
Proceeds From Issuing Shares $392.1m $363.9m $296.2m $960.1m $0
Purchase Of Intangible Assets Classified As Investing Activities $332k $2.1m $3.3m $23.3m $48.8m $3.7m $9.6m $567k $65.4m $155k
Net profit / (loss) (-) $54.0m ($115.7m) ($29.3m) $149.8m ($305.4m) ($103.2m) ($218.0m) $211.7m $74.1m $320.9m
Increase in provisions $7k $1k $45.5m
Adjustment for non-cash transactions ($47.5m) $48.3m $21.8m $248.0m $230.7m $57.7m $117.3m $99.3m ($4.9m) $127.2m
Adjustment for items to disclose under investing and financing cash flows ($14k) ($668k) ($5.1m) ($2.5m) ($28.8m) ($3.8m) ($16.7m) ($76.2m) ($42.3m)
Decrease in deferred income ($207.8m) ($453.7m) ($383.6m) ($661.1m) ($255.5m) ($1.1b)
Cash used in operations $240.1m ($147.9m) ($146.0m) $3.2b ($427.0m) ($493.5m) ($488.5m) ($463.9m) ($417.3m) ($307.9m)
Purchase of and expenditure in intangible fixed assets ($332k) ($2.1m) ($3.3m) ($23.3m) ($48.8m) ($3.7m) ($9.6m) ($567k) ($65.4m) ($155k)
Cash out from disposal of subsidiaries, net of cash disposed of ($8.9m) $19.4m
Cash out from acquisition of subsidiaries, net of cash acquired ($115.3m) ($7.0m)
Cash advances and loans to third parties ($10.0m) ($20.0m)
Acquisition of financial assets held at fair value ($14.0m) ($36.9m)
Proceeds from capital and share premium increases from exercise of subscription rights $28.3m $3.3m $6.7m $1.8m

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.